Brief: Biomed Lublin Starts Talks With ABM On Commercialising Use Of Immunoglobulin On COVID-19 Patients

Synthaverse SA

16/03/2021 07:57

March 16 (Reuters) - Biomed Lublin Wytwornia Surowic i
Szczepionek SA  BML.WA :
    * STARTS TALKS WITH POLAND'S MEDICAL RESEARCH AGENCY ON
COMMERCIALISING CLINICAL TRIAL RESULTS OF USING ANTI SARS COV 2
IMMUNOGLOBULIN ON COVID 19 PATIENTS

Source text for Eikon:  ID:nEM9vpXY0a 
Further company coverage:  BML.WA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))